Onyx Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: South San Francisco CA United States (1992)
Status: Acquired by Amgen (2013)

Organization Overview

First Clinical Trial
2009
NCT00813293
First Marketed Drug
2012
carfilzomib (kyprolis)
First NDA Approval
2012
carfilzomib (kyprolis)
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Onyx/Amgen | ONYX THERAP | Onyx Therapeutics, Inc.

Indications

Approved Indications


 

Multiple Myeloma

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Hypertension (Phase 2)

Hypertension, Portal (Phase 2)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 2)

Leukemia, Plasma Cell (Phase 1)

Liver Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Multiple Myeloma (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Preleukemia (Phase 2)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 26
  • # of Trial APIs: 17